Delayed
Japan Exchange
02:00:00 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
1,161
JPY
|
+1.57%
|
|
+0.87%
|
-8.08%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
146,997
|
109,275
|
112,574
|
82,566
|
71,375
|
86,993
|
-
|
-
|
Enterprise Value (EV)
1 |
148,811
|
111,095
|
109,049
|
74,002
|
59,122
|
72,430
|
68,750
|
65,175
|
P/E ratio
|
19
x
|
14.1
x
|
56.2
x
|
11
x
|
10.4
x
|
11
x
|
11
x
|
10.6
x
|
Yield
|
1.59%
|
2.13%
|
3.5%
|
3.7%
|
4.15%
|
3.38%
|
3.47%
|
3.64%
|
Capitalization / Revenue
|
3.23
x
|
2.11
x
|
2.2
x
|
1.6
x
|
1.38
x
|
1.7
x
|
1.65
x
|
1.59
x
|
EV / Revenue
|
3.27
x
|
2.15
x
|
2.13
x
|
1.44
x
|
1.14
x
|
1.42
x
|
1.31
x
|
1.19
x
|
EV / EBITDA
|
12.7
x
|
9.5
x
|
8.93
x
|
6.39
x
|
4.77
x
|
5.74
x
|
5.57
x
|
5.17
x
|
EV / FCF
|
-50.8
x
|
41.5
x
|
10.4
x
|
8.12
x
|
5.51
x
|
10
x
|
10.7
x
|
10.1
x
|
FCF Yield
|
-1.97%
|
2.41%
|
9.57%
|
12.3%
|
18.2%
|
9.96%
|
9.33%
|
9.88%
|
Price to Book
|
3.16
x
|
2.13
x
|
2.19
x
|
1.5
x
|
1.27
x
|
1.5
x
|
1.38
x
|
1.28
x
|
Nbr of stocks (in thousands)
|
80,414
|
80,231
|
80,353
|
80,396
|
77,920
|
74,929
|
-
|
-
|
Reference price
2 |
1,828
|
1,362
|
1,401
|
1,027
|
916.0
|
1,161
|
1,161
|
1,161
|
Announcement Date
|
4/26/19
|
5/12/20
|
5/7/21
|
5/11/22
|
5/10/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
45,525
|
51,761
|
51,286
|
51,469
|
51,750
|
51,100
|
52,640
|
54,867
|
EBITDA
1 |
11,702
|
11,698
|
12,207
|
11,584
|
12,403
|
12,617
|
12,350
|
12,617
|
EBIT
1 |
10,526
|
10,434
|
10,367
|
9,973
|
10,837
|
11,140
|
11,109
|
11,411
|
Operating Margin
|
23.12%
|
20.16%
|
20.21%
|
19.38%
|
20.94%
|
21.8%
|
21.1%
|
20.8%
|
Earnings before Tax (EBT)
1 |
10,801
|
10,425
|
4,540
|
10,041
|
9,789
|
11,293
|
11,175
|
11,477
|
Net income
1 |
7,723
|
7,748
|
2,000
|
7,484
|
6,891
|
8,072
|
7,997
|
8,210
|
Net margin
|
16.96%
|
14.97%
|
3.9%
|
14.54%
|
13.32%
|
15.8%
|
15.19%
|
14.96%
|
EPS
2 |
96.05
|
96.55
|
24.91
|
93.13
|
88.22
|
105.3
|
105.7
|
109.6
|
Free Cash Flow
1 |
-2,927
|
2,677
|
10,436
|
9,115
|
10,736
|
7,214
|
6,412
|
6,438
|
FCF margin
|
-6.43%
|
5.17%
|
20.35%
|
17.71%
|
20.75%
|
14.12%
|
12.18%
|
11.73%
|
FCF Conversion (EBITDA)
|
-
|
22.88%
|
85.49%
|
78.69%
|
86.56%
|
57.18%
|
51.92%
|
51.03%
|
FCF Conversion (Net income)
|
-
|
34.55%
|
521.8%
|
121.79%
|
155.8%
|
89.37%
|
80.19%
|
78.42%
|
Dividend per Share
2 |
29.00
|
29.00
|
49.00
|
38.00
|
38.00
|
39.25
|
40.25
|
42.25
|
Announcement Date
|
4/26/19
|
5/12/20
|
5/7/21
|
5/11/22
|
5/10/23
|
-
|
-
|
-
|
Fiscal Period: March |
2020 S1
|
2021 S1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 S1
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
24,173
|
24,453
|
12,518
|
25,130
|
13,879
|
12,460
|
12,969
|
12,520
|
25,489
|
13,009
|
13,252
|
12,954
|
12,178
|
25,132
|
13,170
|
12,843
|
12,810
|
12,516
|
-
|
13,022
|
13,034
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
4,851
|
4,369
|
2,362
|
4,681
|
2,823
|
2,469
|
2,707
|
2,412
|
5,119
|
2,812
|
2,906
|
3,176
|
2,296
|
5,472
|
2,978
|
2,683
|
2,801
|
2,461
|
5,600
|
2,691
|
2,698
|
Operating Margin
|
20.07%
|
17.87%
|
18.87%
|
18.63%
|
20.34%
|
19.82%
|
20.87%
|
19.27%
|
20.08%
|
21.62%
|
21.93%
|
24.52%
|
18.85%
|
21.77%
|
22.61%
|
20.89%
|
21.86%
|
19.66%
|
-
|
20.67%
|
20.7%
|
Earnings before Tax (EBT)
1 |
4,841
|
4,007
|
2,393
|
4,811
|
2,706
|
2,524
|
2,670
|
2,439
|
5,109
|
1,584
|
3,096
|
3,240
|
2,386
|
5,626
|
2,959
|
2,658
|
2,651
|
2,461
|
-
|
2,691
|
2,748
|
Net income
1 |
3,555
|
2,784
|
1,889
|
3,591
|
1,931
|
1,962
|
1,946
|
1,756
|
3,702
|
869
|
2,320
|
2,330
|
1,703
|
4,033
|
2,140
|
1,948
|
1,913
|
1,774
|
-
|
1,970
|
2,011
|
Net margin
|
14.71%
|
11.39%
|
15.09%
|
14.29%
|
13.91%
|
15.75%
|
15.01%
|
14.03%
|
14.52%
|
6.68%
|
17.51%
|
17.99%
|
13.98%
|
16.05%
|
16.25%
|
15.17%
|
14.93%
|
14.18%
|
-
|
15.12%
|
15.43%
|
EPS
|
44.29
|
34.68
|
23.49
|
44.67
|
24.02
|
24.44
|
24.73
|
-
|
47.27
|
11.20
|
-
|
30.03
|
-
|
52.41
|
28.29
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
38.00
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/5/19
|
10/28/20
|
11/1/21
|
11/1/21
|
1/28/22
|
5/11/22
|
7/29/22
|
11/2/22
|
11/2/22
|
2/1/23
|
5/10/23
|
8/2/23
|
11/6/23
|
11/6/23
|
2/2/24
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
1,814
|
1,820
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
3,525
|
8,564
|
12,253
|
14,563
|
18,243
|
21,818
|
Leverage (Debt/EBITDA)
|
0.155
x
|
0.1556
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2,927
|
2,677
|
10,436
|
9,115
|
10,736
|
7,214
|
6,412
|
6,438
|
ROE (net income / shareholders' equity)
|
17.6%
|
15.8%
|
3.9%
|
14.1%
|
12.4%
|
14%
|
13.5%
|
13.2%
|
ROA (Net income/ Total Assets)
|
16.8%
|
14.6%
|
14.2%
|
13.7%
|
14.8%
|
12.6%
|
12.6%
|
12.6%
|
Assets
1 |
46,005
|
53,059
|
14,066
|
54,665
|
46,710
|
64,207
|
63,721
|
65,155
|
Book Value Per Share
2 |
578.0
|
641.0
|
638.0
|
683.0
|
721.0
|
775.0
|
839.0
|
906.0
|
Cash Flow per Share
2 |
112.0
|
115.0
|
47.80
|
117.0
|
112.0
|
131.0
|
131.0
|
138.0
|
Capex
1 |
1,712
|
2,472
|
996
|
1,516
|
1,706
|
2,791
|
2,305
|
2,339
|
Capex / Sales
|
3.76%
|
4.78%
|
1.94%
|
2.95%
|
3.3%
|
5.46%
|
4.38%
|
4.26%
|
Announcement Date
|
4/26/19
|
5/12/20
|
5/7/21
|
5/11/22
|
5/10/23
|
-
|
-
|
-
|
Last Close Price
1,161
JPY Average target price
1,450
JPY Spread / Average Target +24.89% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.08% | 553M | | +13.16% | 128B | | -8.76% | 10.65B | | +3.60% | 8.82B | | +19.75% | 7.19B | | +22.28% | 4.99B | | +7.55% | 3.4B | | -0.21% | 3.03B | | -4.80% | 2.14B | | -4.72% | 2B |
Medical Devices & Implants
|